Immunostimulants drugs - versus control - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.91 [0.83, 0.99]< 18%33 studies (33/-)98.6 %some concerncritical moderatecrucial-
death or transfer to ICU 0.65 [0.35, 1.22]< 10%1 study (1/-)90.9 %NAnot evaluable crucial-
deaths 0.91 [0.84, 0.98]< 19%56 studies (56/-)99.3 %some concerncritical moderatecrucial1
deaths (time to event analysis only) 0.91 [0.74, 1.11]< 18%10 studies (10/-)82.4 %some concernlow moderatecrucial-
clinical deterioration 0.84 [0.69, 1.04]< 110%6 studies (6/-)94.7 %some concernnot evaluable moderateimportant-
clinical improvement 1.08 [0.96, 1.22]> 136%16 studies (16/-)90.4 %some concernlow moderateimportant-
clinical improvement (14-day) 1.37 [0.69, 2.72]> 156%4 studies (4/-)81.3 %some concernnot evaluable moderateimportant-
clinical improvement (28-day) 1.61 [0.96, 2.70]> 167%6 studies (6/-)96.3 %some concernserious moderateimportant-
clinical improvement (7-day) 1.10 [0.80, 1.51]> 135%4 studies (4/-)72.6 %some concernnot evaluable moderateimportant-
clinical improvement (time to event analysis only) 1.16 [0.96, 1.40]> 142%9 studies (9/-)93.9 %some concernserious moderateimportant-
death or ventilation 0.94 [0.87, 1.03]< 159%9 studies (9/-)90.3 %some concernnot evaluable moderateimportant-
hospital discharge 1.09 [0.98, 1.21]> 155%8 studies (8/-)94.5 %some concernnot evaluable moderateimportant-
hospitalization 1.00 [0.14, 7.34]< 10%1 study (1/-)50.0 %NAnot evaluable important-
mechanical ventilation 0.82 [0.64, 1.06]< 121%12 studies (12/-)93.5 %some concerncritical moderateimportant1
mechanical ventilation (time to event analysis only) 0.97 [0.62, 1.52]< 10%2 studies (2/-)55.5 %some concernnot evaluable moderateimportant-
radiologic improvement (14-day) 2.33 [0.45, 12.00]> 10%1 study (1/-)84.4 %NAnot evaluable important-
viral clearance 2.71 [0.82, 8.92]> 188%6 studies (6/-)94.9 %some concernnot evaluable moderateimportant-
viral clearance (time to event analysis only) 0.81 [0.56, 1.18]> 10%1 study (1/-)13.7 %NAnot evaluable important-
viral clearance by day 14 1.08 [0.07, 16.52]> 197%5 studies (5/-)52.2 %some concernnot evaluable moderateimportant-
viral clearance by day 7 1.59 [0.67, 3.76]> 173%4 studies (4/-)85.4 %some concernnot evaluable moderateimportant-
ICU admission 0.60 [0.41, 0.88]< 10%7 studies (7/-)99.6 %some concernnot evaluable moderatenon important-
recovery 1.12 [0.97, 1.28]> 17%4 studies (4/-)94.3 %lownot evaluable highnon important-

safety endpoints 00

composite safety outcome 1.56 [0.78, 3.11]< 10%1 study (1/-)10.3 %NAnot evaluable important-
serious adverse events 1.16 [0.98, 1.36]< 112%10 studies (10/-)3.9 %some concernlow moderateimportant-
superinfection 0.18 [0.02, 1.59]< 10%1 study (1/-)93.8 %NAnot evaluable important-
adverse events 1.13 [0.91, 1.40]< 10%6 studies (6/-)12.9 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.